Addition of clindamycin to whole-cell cultures of Streptomyces coelicolor MuLLER resulted in the loss of in vitro activity against organisms sensitive to clindamycin. In the past few years we have been involv- Chem. Soc. 93: 534, 1971 after treatment of the sample under evaluation with crude alkaline phosphatase. This crude enzyme preparation exhibited both phosphomono-and phosphodiesterase activities. Fractions containing the clindamycin bioconversion products did not show any bioactivity before treatment with the enzyme.
Incubation of these fractions with alkaline phosphatase afforded clindamycin which was easily identified by TLC.
The clindamycin bioconversion products, which for convenience would be designated as clindamycin 3-ribonucleotides and clindamycin 3-phosphate, were isolated from culture filtrates by adsorption on Amberlite XAD-2 followed by elution with aqueous methanol. Chromatography of the methanolic eluates on Dowex-1 (acetate) resulted in the separation of clindamycin 3-ribonucleotides (isolated from the spent) from most of clindamycin 3-phosphate (eluted from the column with 5 % aqueous acetic acid). Amberlite XAD-2 chromatography of the crude clindamycin 3-ribonucleotides followed by counter double current distribution (1-butanol-water, 1:1 v/v) yielded a mixture of bioinactive, UVabsorbing compounds which afforded clindamycin by treatment with venom phosphodiesterase.
Chromatography of the mixture on DEAE-Sephadex (acetate) using tris-acetate (pH 8.0, 0.1 -0.2 M) buffer gave eight compounds designated A, B, C, D, E, F, G and H in order of elution from the column * Snake venom phosphodiesterase (phosphodiesterase I) catalyzes the hydrolysis of oligonucleotides (ribo-or deoxyribo-) with free 3'-hydroxyl end group to yield mononucleoside 5'-phosphates5). ** Spleen phosphodiesterase (phosphodiesterase II) acts as an exonuclease and yields nucleoside-3'-phosphates. A free 5'-hydroxyl group is necessary5).
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Chemical Shift (8) 
Clindamycine part
Ribosef part
Purine or pyrimidine partf a Relative to tetramethylsilane using dioxane as an internal standard; D20 was used as solvent . b Compounds:
A , clindamycin-3-(5'-cytidylate), The results obtained by chemical hydrolyses (Table 4 ) support the structures postulated above.
As expected6), the purine ribonucleotides (compounds D and G) afforded purines** and ribose*** by treatment with 1 N HCl while the pyrimidine nucleotides A and E gave the corresponding nucleosides, cytidine and uridine respectively. Hydrolysis of all four nucleotides with 6 N HCl or 72% perchloric acid resulted in liberation of purine** or pyrimidine bases, while treatment with 0.1 N NaOH gave in all cases the corresponding nucleosides.
The PMR spectra of compounds A, D, E and G (Table 6 ) are in agreement with the assigned struc- CMR studies show that a simple comparison of the spectra of clindamycin and of the ribonucleotides A, D, E and G (Table 7 and Fig. 4 ) is sufficient to establish the structure of these compounds.
As shown in Table 7 Table 7 ). This is due to the deshielding effect of the phosphate group attached at C-3 of these compounds'. Furthermore, the chemical shifts of the carbons of ribose and the purine or pyrimidine moieties of compounds A, D, E and G are almost identical to the chemical shifts (see Table 8 ) of the corresponding nucleoside 5'-phosphates, i.e. cytidine . This is also due to the deshielding effect of the phosphate group at C-5' of ribose. We conclude, therefore, that the CMR studies indicate a phospho diester* bond between C-3 of clindamycin and C-5' of the ribose moiety and specifically that compounds A, D, E and G have structures 3, 4, 5 and 6 respectively. The isolation of compounds B, C and F was mentioned earlier in this paper (see Fig. 2 ). Compound B had UV spectra identical to those of clindamycin 3-(5'-adenylate) (4). Treatment with alkaline phosphatase resulted in production of clindamycin sulfoxide and adenosine. Spleen phosphodiesterase did not affect compound B, while venom phosphodiesterase yielded clindamycin sulfoxide and adenosine 5'-phosphate. This enzymatic behavior suggests the clindamycin sulfoxide-(5'-adenylate) structure for compound B. The point of the phosphodiester attachment at the aminosugar moiety of clindamycin is not known. The formation of clindamycin sulfoxide-(5'-adenylate) is not surprising since clindamycin can be transformed to clindamycin sulfoxide by streptomycetes3).
Compound C had UV, IR and NMR spectra identical to those of clindamycin 3-(5'-adenylate) (4).
Compound C yielded clindamycin and adenosine or adenosine 5'-phosphate by treatment with alkaline phosphatase or venom phosphodiesterase, respectively, and was not affected by spleen phosphodiesterase. These data indicate a clindamycin-(5'-adenylate). The clindamycin site of the phosphodiester linkage is not known. A clindamycin 4-(5'-adenylate) structure is possible and would be produced by rearrangement of the nucleotide moiety from C-3 to C-4 of clindamycin under the isolation conditions.
Compound F had UV, IR and enzymatic behavior identical to that of clindamycin 3-(5'-guanylate) (6) . We consider the structure of clindamycin 4-(5'-adenylate) for compound F although the point of attachment of the phosphodiester bond at C-4 of clindamycin has not been established.
Biological
Properties of Clindamycin 3-Ribonucleotides
As mentioned earlier, the isolated clindamycin 3-ribonucleotides and clindamycin 3-phosphate were inactive in vitro against several organisms including Staphylococcus aureus . However, these compounds were found to protect S. aureus infected mice when they were administered subcutaneously.
The observed CD;50's9) were as follows: clindamycin 3-(5'-adenylate), 30 mg/kg; clindamycin 3-(5'-uridylate), 37 mg/kg; clindamycin 3-(5'-guanylate), 26 mg/kg and clindamycin 3-phosphate, 9.8 mg/kg.
The in vivo activity of the clindamycin 3-ribonucleotides and clindamycin 3-phosphate is presumably due to clindamycin and/or its bioactive metabolites produced by biotransformation of these compounds. Enzymatic reactions involving ribonucleotides and leading "active intermediates" (aminoacid activation, coenzyme A biosynthesis) are well known. However, the described biotransformation of clindamycin is the first reported example of modification of an antibiotic involving either adenosine-5'-phosphate (adenylation) or one of the remaining 5-ribonucleotides, guanosine-5'-phosphate, cytidine-5'-phosphate and uridine-5'-phosphate.
Experimental
Spectroscopic Methods Proton magnetic resonance spectra were recorded on a Varian XL-100-15 spectrometer operating at 100 MHz. Spectra were run in D20 using sodium 2,2-dimethyl-2-silapentane-5-sulfonate (SDSS) as internal reference.
Carbon magnetic resonance spectra were recorded on a Varian CFT-20 spectrometer. D20 was used as the solvent and dioxane as an internal reference.
PMR and CMR chemical shifts are reported as ppm relative to tetramethylsilane. Infrared spectra were obtained in mineral oil suspension on a Digilab Model 14D FOURIER Transform Spectrometer.
Assay of Clindamycin and Clindamycin Bioconversion Products Since clindamycin 3-ribonucleotides and clindamycin 3-phosphate lack in vitro antibacterial activity, their formation from clindamycin can be followed easily by measuring the loss of such antibiotic activity. To determine the amounts of clindamycin in culture filtrates or reaction mixtures a standard assay with Sarcina lutea ATCC 9341 as described by COATS and ARGOUDELts4) was employed. To assay for the presence of clindamycin 3-ribonucleotides and clindamycin 3-phosphate in fermentation beers, extracts and purified materials, the phosphodiester or phosphate ester bond was first hydrolyzed with crude alkaline phosphatase by the procedures described below. Clindamycin in the hydrolysate was determined by standard assay.
Enzymatic Hydrolyses Alkaline Phosphatase: Stock solutions (0.5 mg/ml) of calf intestine alkaline phosphatase, EC 3.1.3.1 (Calbiochem) were prepared in tris (hydroxymethyl) aminomethane (Tris)-hydrochloride buffer, 0.5 M pH 8.0. Samples to be treated were diluted 1 : 2 with the enzyme buffer mixture and were incubated at 28°C for 18 hours. Snake Venom Phosphodiesterase: Stock solutions (1 mg/ml) of purified snake venom phosphodiesterase (Worthington Biochemicals, Freehold, N.J.) were prepared in distilled water. Incubation mixtures contained 0.3 ml of a solution (1 mg/ml) of the sample to be treated in water, 0.2 ml of 0.1 M Tris-hydrochloride buffer, pH 8.6 and 0.1 ml of the enzyme stock solution. Incubation was carried out at 28°C for 18-24 hours.
Spleen Phosphodiesterase: Stock solutions of spleen phosphodiesterase (Worthington Biochemicals) were prepared in distilled water so that the activity (Worthington) was ca 2 -3 units/ml. Incubation mixtures contained 0.3 ml of a solution (1 mg/ml) of the sample to be treated in water, 0.1 ml of 0.25 M sodium succinate-hydrochloride buffer, pH 6.5 and 0.2 ml of the enzyme stock solution. Incubation was carried out at 28°C for 18-24 hours.
Chemical Hydrolyses Hydrolysis Using 1 N Aqueous Hydrochloric Acid: The procedure of HOTCHKISS11) was used. The sample to be hydrolyzed (ca 30-50 mg) was dissolved in 5 ml of 1 N aqueous hydrochloric acid. The solution was kept at 100°C for 1 hour. The hydrolysate was then concentrated to dryness. The residue was dissolved in 2 ml of water and the solution was analyzed by UV determination and thinlayer chromatography.
Hydrolysis Using 6 N Aqueous Hydrochloric Acid: The sample to be hydrolyzed (ca 30-50 mg) was dissolved in 5 ml of 6 N aqueous hydrochloric acid. The solution was kept at reflux for 2 hours; it was then cooled and analyzed by UV determination and thin-layer chromatography.
Hydrolysis Using Perchloric Acid: The procedure of MAR5HAK and VOGELI2) was used. The sample to be hydrolyzed (30-50 mg) was dissolved in 5 ml of 72 % perchloric acid and the solution was kept at 100°C for 1 hour. The hydrolysate was analyzed by determination of its UV spectra at different pH's, and thin-layer chromatography.
Hydrolysis Using 0.1 N Sodium Hydroxide: The procedure of LORING and his co-workers13) was used. The sample to be hydrolyzed (30-50 mg) was dissolved in 5 ml of 0.1 N aqueous sodium hydroxide, and kept at 100°C for 2.5 hours. The hydrolysate was then analyzed by UV determination and thin-layer chromatography.
Thin-Layer Chromatographic Analysis of Preparations and Chemical or Enzymatic Hydrolysates
The production and purification of clindamycin 3-ribonucleotides and clindamycin 3-phosphate was followed by assay against S. lutea (see above) and by TLC using silica gel G and methyl ethyl ketoneacetone -water (186: 52: 20, v/v) or ethyl acetate -acetone -water (8: 5: 1) as the solvent systems. Clindamycin and other bioactive metabolites of clindamycin were detected by bioautography on agar seeded with S. lutea.
The products of enzymatic or chemical hydrolysis of clindamycin 3-nucleotides and clindamycin 3-phosphate were separated by the following TLC systems:
A: Silica gel GF plates (Analtech Inc.); water as the solvent system. B: Silica gel GF plates; n-propyl alcohol-conc. ammonium hydroxide-water (55: 10: 35, v/v). C: NM-Polygram Cellulose 300 (Brinkman Instruments Inc.); 1-butanol -water -formic acid (77: 13: 10, v/v). UV absorbing materials were detected by a short wavelength UV lamp. Bioinactive, UV-nonabsorbing materials were detected by a permanganate-periodate spray reagent. Ribose was detected by spraying with aniline acid phthalate reagent (1.66 g of phthalic acid and 0.93 g of aniline in 100 ml of water-saturated 1-butanol) and by permanganate-periodate.
Bioactive materials (i.e. clindamycin) were detected by bioautography on agar seeded with S. lutea.
Periodate Oxidation Material to be oxidized (ca 0.2 mmoles) was dissolved in 10 ml of water and mixed with 10 ml of sodium metaperiodate solution (4 g of NaIO4 in 100 ml of water; 1.88 mmoles of periodate per 10 ml of solution). The consumption of periodate was determined at different time intervals using the FLEURY-LANGE procedure14).
Fermentation Procedures Seed cultures of S. coelicolor MULLER UC-5240 (NRRL 3532) were prepared in a medium consisting of glucose monohydrate (Cerelose), 25 g/liter and Pharmamedia (Traders Oil Mill Co., Fort Worth, Texas) 25 g/liter. The cultures were incubated at 28°C for 72 hours on a rotary shaker. A fermentation medium consisting of glucose monohydrate, 20 g/liter; yeast extract, 2.5 g/liter; NZamine B (Sheffield Chemical, Norwich, N.Y.), 5 g/liter; sodium nitrate, 3.0 g/liter; dipotassium phosphate, 1.0 g/liter; magnesium sulfate, 0.5 g/liter; potassium chloride, 0.5 g/liter and ferrous sulfate, 0.1 g/liter was inoculated with the 72-hour seed culture at a ratio of 5 % (v/v). The pH of the medium was adjusted to 7.2. Cultures were incubated at 28°C on a rotary shaker (250 rpm, 6-cm stroke). Clindamycin hydrochloride (50 mg/liter) was added 24 hours after inoculation. Culture filtrates were harvested after 48 hours of incubation at which time the added clindamycin was found to be completely inactivated.
Isolation and Purification Procedures Isolation of Clindamycin 3-Ribonucleotides and Clindamycin 3-Phosphate from Fermentation Broth. Adsorption on Amberlite XAD-2: Fermentation broth (ca 490 liters) containing inactivated clindamycin was filtered at harvest pH (6.5) by using filter aid. The mycelial cake was washed with 50 liters of water and discarded. The clear filtrate and the wash were combined and passed over a column prepared from 22 kg of Amberlite XAD-2 (Rohm and Haas Co., Philadelphia, Pa.), at a flow rate of 1 liter/minute. The column was washed with 100 liters of water and then eluted with 120 liters of methanol -water (60: 40, v/v). Fractions containing inactivated clindamycin were combined and VOL. XXX NO. 6 THE JOURNAL OF ANTIBIOTICS this solution was purified further by ion-exchange chromatography as described below. Dowex-1 Chromatography:
The column was prepared from 22 kg Dowex-1 (X-4) in the acetate form. The solution containing inactivated clindamycin, obtained as described above, was passed through the column. The spent, found to contain mainly clindamycin 3-ribonucleotides and small amounts of clindamycin 3-phosphate was concentrated to dryness to give 877 g of crude preparation (Prep A) which was purified as discussed below. The column was washed with 100 liters of water then eluted with 70 liters of 5 % aqueous acetic acid. The acetic acid eluates yielded 89.4 g of material which contained clindamycin 3-phosphate and small amounts of clindamycin 3-ribonucleotides.
Amberlite XAD-2 Chromatography: Prep A, 776 g, (isolated as described above) was dissolved in 1.5 liters of water. The pH of the solution was adjusted to 7.5 with concentrated ammonium hydroxide and the solution was passed over a column containing 4 liters of Amberlite XAD-2. The spent was collected as one fraction and was discarded. The column was washed with 8 liters of water which was also discarded. The column was then eluted with methanol -water (90: 10). Selected fractions (20-ml each) were tested for activity against S. lutea before and after treatment with alkaline phosphatase. Fractions yielding bioactive materials after enzymatic treatment were combined, concentrated to an aqueous solution which was then freeze-dried to yield 64.7 g of a preparation containing clindamycin 3-ribonucleotides and clindamycin 3-phosphate. This material was purified by counter double current distribution described below.
Counter Double Current Distribution: Twenty-one g of the material obtained as described above was dissolved in 100 ml of each phase of the solvent system consisting of equal volumes of 1-butanolwater (1: 1). The solutions were added in the center tubes of an all glass counter double current distribution apparatus (100 tubes, 25 ml/phase). The distribution was analyzed after 100 transfers by determination of bioactivity of selected fractions before and after treatment with crude alkaline phosphatase. Fractions yielding bioactive materials after treatment with alkaline phosphatase were combined, concentrated to an aqueous solution and freeze-dried to give 6.9 g of purified mixture of clindamycin 3-ribonucleotides containing small amounts of clindamycin 3-phosphate.
Two additional counter double current distribution runs using conditions identical to those described above yielded an additional 14.0 g of material.
DEAE-Sephadex Chromatography: Five hundred g of DEAE-Sephadex (A-25) was stirred for 1 hour with water and for 2 hours with 0.5 N aqueous sodium hydroxide. The ionic exchanger was washed with water till the pH was ca 7.5. The material was then stirred for 2 hours with 0.5 N aqueous acetic acid washed with water to a neutral pH, and poured into a glass column. The column was washed with 4 liters of water and 4 liters of 0.1 % aqueous solution of tris-(hydroxymethyl)-aminomethane (THAM).
Thirteen g of the material obtained by counter double current distribution was dissolved in 100 ml of water. This solution was adjusted to pH 9.0 with concentrated ammonium hydroxide and added on the top of the column. The column was then eluted as follows. Fractions (20 ml each) were collected. The materials obtained were designated as compounds A, B, C, D, E, F, G and H. Characterization of these materials has been discussed earlier in this paper.
